Status:
COMPLETED
Platelet Aggregation in COVID-19 Patients
Lead Sponsor:
Mansoura University
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Context: Hypercoagulable state associated with COVID-19 is one of the pathologic events that noticed in different waves of COVID-19 pandemics and leads to serious consequences in mortality and morbidi...
Detailed Description
This observational, case control study included 50 adult patients with positive COVID-19 PCR test recruited from isolation department of Mansoura university hospital from July 2021 to May 2022 as a st...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old.
Exclusion
- • Patients with thrombocytopenia and thrombocytosis defined as platelet count less than 100,000/ µL, count more than 450,000 / µL respectively
- Patients with hematocrit abnormalities as less than 34% or greater than 55%
- Patients with disseminated intravascular coagulation (DIC)
- Active malignancy
- Liver disease as such chronic hepatitis, cirrhosis or liver cell failure.
- Any hematological disorders as hemophilia or thalassemia.
- Patients on invasive mechanical ventilation as endotracheal intubation and mechanical ventilation itself are factors for having a higher mean platelet volume (MPV) which means that platelets are larger than average which are more adhesive and likely to aggregate in vitro. Patients receiving aspirin, non-steroidal anti-inflammatory drugs, antiplatelet drugs or any other medications that can influence platelet function (14 days prior to blood sample collection)
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT06097429
Start Date
July 1 2021
End Date
February 1 2022
Last Update
October 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Al Mansurah, Egypt, 35516